On Oct. 29, Bukwang Pharm announced that it successfully hosted the 2nd TVM Capital Asia Conference on the outlook of the Korean pharmaceutical market, growth strategies and technology exchange. Business strategists and researchers of foreign and local pharmaceutical companies, along with investors in the biotech and pharmaceutical industries, attended the event.
The conference was co-hosted by Bukwang Pharm and TVM Capital Life Science. Kim Myung-ki, executive director from Interbase; Dr. Mirko Scherer from TVM China; Thomas Mathers, and CEO of Colucid Pharmaceuticals were invited to speak. They spoke on such topics as the outlook of Korea’s biotech and pharmaceutical market and growth strategy, pharmaceutical market trend in China and investment strategy, and Lasmiditan, a migraine drug developed by Colucid, and partnership and strategy.
A guest from a pharmaceutical company said, “The conference provided useful information on business strategy and developing business relations with investors for the pharmaceutical companies.” A representative from an investment company commented, “The conference provided information on foreign investors and their strategies. Also, the programs of the conference covered information on the growth potential of both local and foreign pharmaceutical companies and ways to partner with these companies.”
A spokesperson from Bukwang Pharm said, “For this year’s conference, we sent invitations to pharmaceutical companies and investors beforehand with a view to providing a close networking environment for businesses. And we are planning to continue the tradition of providing a networking venue.”
The TVM conference on pharmaceutical companies and bio-ventures is regularly held in Canada and Austria. In Asia, the first conference was held in October last year, hosted by Bukwang Pharm. Tilted Global Cooperation in New Drug Development, the conference was successful.
TVM Capital Life Science is a globally renowned venture capital focusing on pharmaceutical and biotech companies. For the last 30 years, TVM Capital has made investments in 130 companies and has introduced investors to new bio ventures. Bukwang Pharm is participating both as strategic and limited partner along with Eli Lilly in the fund named Seven, one of a series of funds developed by TVM Capital Life Science.